The specific objectives of the Clinical Research Support Office (CRSO) are to: ? provide streamlined protocol development, activation and implementation, and reduce the time to protocol activation ? increase the quality and quantity of investigator-initiated clinical trials and facilitate the translational research efforts of the Center by providing assistance in protocol development, implementation and data capture ? provide infrastructure for the conduct of early phase clinical trials ? provide a central core of personnel with expertise in all types of clinical trials management including protocol development and trial design, regulatory, compliance, and financial management ? provide central oversight of research personnel (clinical research coordinators and data managers), including initial and ongoing training, education, monitoring, and mentorship ? serve as the central office of record for all clinical trials conducted at the HDFCCC ? increase the participation of volunteer subjects in clinical trials with an emphasis on diversity ? seamlessly integrate informatics and biostatistical support provided by the Biostatistics and Translational Informatics Cores, including ensuring access to and training for a web-based protocol, data capture, and management system managed by the Translational Informatics Core The Clinical Research Support Office serves as the Office of Record and comprises several units, including the Early Phase Clinical Trials Unit, the Finance Unit, the Protocol Development and Regulatory Unit, and the Research Personnel Unit. These units work together to provide oversight, infrastructure support and quality control for the Center's entire clinical trials effort.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693950
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$615,024
Indirect Cost
$225,575
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Chen, Justin; Weiss, William A (2014) When deletions gain functions: commandeering epigenetic mechanisms. Cancer Cell 26:160-1
Johnson, Brett E; Mazor, Tali; Hong, Chibo et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-93
Witte, John S; Visscher, Peter M; Wray, Naomi R (2014) The contribution of genetic variants to disease depends on the ruler. Nat Rev Genet 15:765-76
Sufiawati, Irna; Tugizov, Sharof M (2014) HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread. PLoS One 9:e88803
Sharma, Vineeta; Witkowski, Andrzej; Witkowska, H Ewa et al. (2014) Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291). Arterioscler Thromb Vasc Biol 34:2254-60
Gustafson, William Clay; Meyerowitz, Justin Gabriel; Nekritz, Erin A et al. (2014) Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26:414-27
Gable, Jonathan E; Lee, Gregory M; Jaishankar, Priyadarshini et al. (2014) Broad-spectrum allosteric inhibition of herpesvirus proteases. Biochemistry 53:4648-60
Cope, Leslie M; Fackler, Mary Jo; Lopez-Bujanda, Zoila et al. (2014) Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS One 9:e105545
Bankoti, Jaishree; Apeltsin, Leonard; Hauser, Stephen L et al. (2014) In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 75:266-76
Ilkanizadeh, Shirin; Lau, Jasmine; Huang, Miller et al. (2014) Glial progenitors as targets for transformation in glioma. Adv Cancer Res 121:1-65

Showing the most recent 10 out of 71 publications